<DOC>
	<DOCNO>NCT01290783</DOCNO>
	<brief_summary>Trial design : - Phase III , FOLFIRI versus FOLF ( HA ) iri ( FOLFIRI regimen `` Hyaluronic acid-Irinotecan '' `` HA-Irinotecan '' ) regimen . - Patients mCRC ( metastatic colorectal cancer ) , 2nd/3rd line irinotecan naïve . - Randomized 1:1 , double-blinded , multi-centre , multi-national ( Australia , Bulgaria , Poland , Serbia , Russia , Ukraine United Kingdom ) . - Dosing regimen : - Irinotecan ( 180 mg/m2 ) HA-Irinotecan ( 180 mg/m2 ) , IV , 90 minute , day 1 ( patient &gt; 75 year age , irinotecan HA-Irinotecan dose must reduce 150 mg/m2 ) . - Leucovorin , 400 mg/m2 , levoleucovorin , 200 mg/m2 , IV 90 minute irinotecan . - 5-fluorouracil ( 5-FU ) , 400 mg/m2 IV bolus day 1 , 1200 mg/m2/day x 2 day ( total 2400 mg/m2 46-48 hour ) continuous infusion . - Repeat every 2 week 8 month . - Patient accrual approximately 12-14 month . - Monitoring 18 month post-randomization . - 390 patient . - Progression Free Survival ( PFS ) primary endpoint . - Safety analysis initial 20 patient .</brief_summary>
	<brief_title>Trial FOLF ( HA ) Iri Versus FOLFIRI mCRC</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>Metastatic colorectal cancer disease progression first second line chemotherapy Irinotecan naïve . ECOG performance status 0 1 . Measurable disease , i.e . least one measurable metastatic lesion ( spiral CT MRI ) . Histological proof colorectal cancer . 18 year age old . Adequately recover least 4 week recent surgery chemotherapy . Women childbearing potential ( WOCBP ) male partner WOCBP must agree use adequate contraception . Patient consent obtain sign accord local and/or national ethic . CT MRI scan chest/abdomen/pelvis within 21 day prior randomization . Hematology do within 14 day prior randomization . Chemistry do within 14 day prior randomization . History malignancy , except adequately treat nonmelanoma skin cancer , curatively treated insitu cancer cervix , solid tumor curatively treat evidence disease &gt; 5 year . Locally advanced recurrent disease . Unsuitability irinotecan include know Gilbert 's syndrome , active inflammatory bowel disease chronic diarrhea great equal grade 2 . Abdominal pelvic radiation therapy within last 12 month . Women pregnant breastfeeding . Any condition ( e.g. , psychological , geographical ) would render protocol treatment dangerous . Significant cardiac disease . Untreated symptomatic brain central nervous system ( CNS ) . Presence pleural effusion ascites require therapeutic thoracocentesis paracentesis . Current partial complete bowel obstruction . Concomitant active infection . Enrolled investigational trial , unless treatment trial discontinue least 30 day prior sign Informed Consent ACO002 study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>mCRC</keyword>
	<keyword>CRC</keyword>
	<keyword>colorectal</keyword>
	<keyword>irinotecan</keyword>
	<keyword>Hyaluronic acid</keyword>
	<keyword>Hyaluronan</keyword>
</DOC>